Colonoscopy Clinical Trial
Official title:
Safety and Efficacy of Dexmedetomidine in Painless Colonoscopy: a Single-center, Randomized Study
104 patients who undergo painless colonoscopy from Decemenber 1,2019 to June 30,2022 will be randomized to two groups: propofol group and dexmedetomidine group. In the dexmedetomidine group,dexmedetomidine was infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. In the propofol group, Propofol was administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 during the whole process.
104 patients who undergo painless colonoscopy from Decemenber 1,2019 to June 30,2022 will be randomized to two groups: propofol group and dexmedetomidine group. In the dexmedetomidine group,dexmedetomidine was infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. In the propofol group, Propofol was administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1.For all patients, if Ramsay sedation scale score reached 3, colonoscope was inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg was administrated as the rescue dose if body movement occurred during colonoscopy The primary outcome was the occurrence of hypotension. Secondary outcomes included the followings:(1) the duration and the maximum decreasing in BP. The time-weighted average which is measured by calculating the area under the threshold (AUT) divided by the total duration of colonoscopy. AUT = (depth of hypotension below a 20% decrease in systolic blood pressure or diastolic blood pressure from pre-procedure baseline or SBP of 90 mm Hg or DBP of 50 mm Hg× time in minutes spent of hypotension); (2) the incidence of bradycardia and hypoxemia, mask-assisted ventilation and body movement;(3) the discharge time , patients and endoscopists satisfaction score. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04101097 -
Training and Validation of Models of Factors to Predict Inadequate Bowel Preparation Colonoscopy
|
||
Completed |
NCT03247595 -
Testing How Well Magnesium Citrate Capsules Work as Preparation for a Colonoscopy
|
N/A | |
Completed |
NCT04214301 -
An Open-Label Preference Evaluation of BLI800
|
Phase 4 | |
Withdrawn |
NCT05754255 -
Comparison of High-flow Oxygen With or Without Nasal Positive Airway Pressure (PAP) During Propofol Sedation for Colonoscopy in an Ambulatory Surgical Center
|
N/A | |
Recruiting |
NCT02484105 -
Comforting Conversation During Colonoscopy: A Trial on Patient Satisfaction
|
Phase 4 | |
Active, not recruiting |
NCT02264249 -
Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation
|
N/A | |
Terminated |
NCT01978509 -
The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopies
|
N/A | |
Completed |
NCT01964417 -
The Comparative Study Between Bowel Preparation Method
|
Phase 3 | |
Recruiting |
NCT01685970 -
Comparison of Same-day 2 Sachets Picosulfate Versus High Volume PEG for Afternoon Colonoscopy
|
Phase 3 | |
Completed |
NCT01518790 -
Short Course, Single-dose PEG 3350 for Colonoscopy Prep in Children
|
N/A | |
Recruiting |
NCT00748293 -
Achievement of Better Examinee Compliance on Colon Cleansing Using Commercialized Low-Residue Diet
|
N/A | |
Completed |
NCT00779649 -
MoviPrep® Versus HalfLytely®, Low-VolUme PEG Solutions for Colon Cleansing: An InvesTigator-blindEd, Randomized, Trial
|
Phase 4 | |
Completed |
NCT00671177 -
Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique
|
N/A | |
Completed |
NCT00380497 -
Pico-Salax Versus Poly-Ethylene Glycol for Bowel Cleanout Before Colonoscopy in Children
|
Phase 4 | |
Recruiting |
NCT00160823 -
Impact of a Self-Administered Information Leaflet on Adequacy of Colonic Cleansing for in-Hospital Patients
|
Phase 3 | |
Completed |
NCT00390598 -
PEG Solution (Laxabon®) 4L Versus Senna Glycoside (Pursennid® Ex-Lax) 36mg and PEG Solution (Laxabon®) 2L for Large Bowel Cleansing Prior to Colonoscopy
|
Phase 2/Phase 3 | |
Completed |
NCT00314418 -
Patient Position and Impact on Colonoscopy Time
|
N/A | |
Completed |
NCT00427089 -
Comparison of 2L NRL994 With NaP Preparation in Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening
|
Phase 3 | |
Completed |
NCT00209573 -
A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Elective Colonoscopy
|
Phase 3 | |
Completed |
NCT05823350 -
The Effect of Abdominal Massage on Pain and Distention After Colonoscopy
|
N/A |